Mostrar el registro sencillo del ítem

dc.contributor.authorAutorBarrera-Avalos, Carlos.
dc.contributor.authorAutorLuraschi, Roberto
dc.contributor.authorAutorAcuña-Castillo, Claudio.
dc.contributor.authorAutorVidal, Mabel
dc.contributor.authorAutorMella-Torres, Andrea.
dc.contributor.authorAutorInostroza-Molina, Ailen.
dc.contributor.authorAutorVera, Rodrigo
dc.contributor.authorAutorVargas, Sergio
dc.contributor.authorAutorHernández, Iván
dc.contributor.authorAutorPerez, Christian
dc.contributor.authorAutorVallejos-Vidal, Eva.
dc.contributor.authorAutorValdés, Daniel
dc.contributor.authorAutorImarai, Mónica
dc.contributor.authorAutorReyes-López, Felipe E.
dc.contributor.authorAutorSandino, Ana María
dc.date.accessionedFecha ingreso2024-09-03T19:19:19Z
dc.date.availableFecha disponible2024-09-03T19:19:19Z
dc.date.issuedFecha publicación2022
dc.identifier.citationReferencia BibliográficaFrontiers in Public Health, 10, 8 p.
dc.identifier.issnISSN2296-2565
dc.identifier.uriURLhttp://repositorio.udla.cl/xmlui/handle/udla/1454
dc.identifier.uriURLhttps://www.frontiersin.org/journals/public-health
dc.description.abstractResumenVaccine administration is one of the most efficient ways to control the current coronavirus disease 2019 (COVID-19) pandemic. However, the appearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can avoid the immunity generated by vaccines. Thus, in patients with a complete vaccine schedule, the infection by SARS-CoV-2 may cause severe, mild, and asymptomatic manifestations of the disease. In this case report, we describe for the first time the clinical symptoms of four patients (three symptomatic; one asymptomatic) from Santiago of Chile, with a complete vaccination schedule with two doses of CoronaVac (Sinovac Life Science) infected with the variant of interest (VOI) B.1.621 (Mu). They were compared with four unvaccinated patients, who had a higher prevalence of symptoms after infection compared to vaccinated patients. In the CoronaVac-vaccinated group, an 80-year-old patient who registered various comorbidities required Invasive mechanical ventilation for 28 days with current home medical recovery discharge. By contrast, in the unvaccinated group, a 71-year-old presented more symptoms with more than 45 days of Invasive mechanical ventilation, which continues to date, presenting greater lung damage than the vaccinated hospitalized patient. This first report evidence differences in the clinical symptomatology of patients vaccinated and non-vaccinated infected with the VOI B.1.621 (Mu) and suggest the protective effects of CoronaVac against this variant
dc.format.extentdc.format.extent8 páginas
dc.format.extentdc.format.extent997.2Kb
dc.format.mimetypedc.format.mimetypePDF
dc.language.isoLenguaje ISOeng
dc.publisherEditorFrontiers Media
dc.sourceFuentesFrontiers in Public Health
dc.subjectPalabras ClavesCase report
dc.subjectPalabras ClavesCoronaVac
dc.subjectPalabras ClavesGenomic surveillance
dc.subjectPalabras ClavesInactivated SARS-CoV-2 vaccine
dc.subjectPalabras ClavesSARS-CoV-2 B.1.621 variant
dc.subject.lcshdc.subject.lcshCOVID-19 (Enfermedad)
dc.titleTítuloDescription of symptoms caused by the infection of the SARS-CoV-2 B.1.621 (Mu) variant in patients with complete coronavac vaccination scheme: first case report from santiago of Chile
dc.typeTipo de DocumentoArtículo
dc.udla.catalogadordc.udla.catalogadorCBM
dc.udla.indexdc.udla.indexWoS
dc.udla.indexdc.udla.indexScience Citation Index Expanded
dc.udla.indexdc.udla.indexSocial Sciences Citation Index
dc.udla.indexdc.udla.indexDOAJ
dc.udla.indexdc.udla.indexMEDLINE
dc.udla.indexdc.udla.indexMEDLINE
dc.identifier.doidc.identifier.doi10.3389/fpubh.2022.797569
dc.facultaddc.facultadFacultad de Medicina Veterinaria y Agronomía


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem